NCT00720148View on ClinicalTrials.gov

A Phase I Trial of Bortezomib and Sunitinib

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Solid Tumors
Interventions
DRUG

Sunitinib and Bortezomib

50 mg/m2, IV (in the vein)on day 5 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Emory University

OTHER

NCT00720148 - A Phase I Trial of Bortezomib and Sunitinib | Biotech Hunter | Biotech Hunter